Pfizer Ltd - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates and issue of duplicate share certificates28-01-2020
28-01-2020
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates and issue of duplicate share certificates27-01-2020
Pfizer Ltd - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates and issue of duplicate share certificates22-01-2020
Pfizer eyes share sale of Glaxo JV in 3-4 years
With annual sales of about $13 billion, it brings under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development15-01-2020
PFIZER LTD. - 500680 - Shareholding for the Period Ended December 31, 2019
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here10-01-2020
Pfizer Ltd - 500680 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 226262 Name of the Signatory :- PRAJEET NAIRDesignation :- Company Secretary and Compliance Officer10-01-2020
PFIZER LTD. - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith Certificate dated January 8, 2020, issued by KFin Technologies Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended December 31, 2019. We request you to take the same on record.10-01-2020
Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf
Repositioning an old brand helps expand the footprint, say analysts08-01-2020
China approves home-grown vaccines, offering alternative to global drugmakers' products
Pfizer's Prevnar 13, which was approved in China in 2016, was the only pneumococcal 13-valent conjugate vaccine available around the world before Walvax's product, the notice said. Walvax's pneumococcal 13-valent conjugate vaccine will be mainly used to immunize children from six weeks through to five years of age from the invasive disease caused by 13 types of bacteria.02-01-2020
Drugmakers from Pfizer to GSK to hike US prices up to 10% on over 200 drugs
More price increases are expected to be announced later this week, which could affect the median and range.01-01-2020